Top Qs
Timeline
Chat
Perspective
PL-6983
Chemical compound From Wikipedia, the free encyclopedia
Remove ads
PL-6983 is a synthetic peptide and selective MC4 receptor agonist which is under development by Palatin Technologies for the treatment of female sexual dysfunction and erectile dysfunction.[1][2] It was developed as a successor to/replacement of bremelanotide (PT-141) due to concerns of the side effect of increased blood pressure seen with the latter in clinical trials.[1][2] Relative to bremelanotide, PL-6983 produces significantly lower increases in blood pressure in animal models.[1][2] The drug has reportedly been in pre-clinical development for all medical indications since 2008.[3] Palatin has stated that "We are focusing development efforts on bremelanotide for [female sexual dysfunction], but are continuing evaluation of PL-6983."[4] The chemical structure of PL-6983 has yet to be made public.
Remove ads
See also
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads